Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
536
NCT00309556
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
Phase: Phase 3
Role: Collaborator
Start: Feb 28, 2005
Completion: Nov 30, 2011